Back Cochrane, M (13 April 2016) 'Doctor to discuss diabetes drug discovery during fifth annual Chu Lecture', University at Buffalo, New Center
Interestingly, L
Emerging digital health technologies, including mobile-based symptom tracking and ecological momentary assessment, can complement traditional clinic-based measurements and provide richer longitudinal data
The treatment begins with a low dosage that gradually increases over 16-20 weeks
How clinicians might think about this (risk vs benefit) GLP-1 receptor agonists have benefits that are not small: strong glucose lowering in many patients weight loss benefits in certain populations, cardiovascular risk reduction sometimes improved adherence compared to multiple daily pills because of weekly dosing options So for many patients, the benefit side of the equation is heavy
[DOI] [PMC free article] [PubMed] [Google Scholar] [24].Alam J, Camhi S, Choi AMK